Corvus Pharmaceuticals Management
Management criteria checks 4/4
Corvus Pharmaceuticals' CEO is Rick Miller, appointed in Feb 2014, has a tenure of 10.17 years. total yearly compensation is $524.24K, comprised of 57.2% salary and 42.8% bonuses, including company stock and options. directly owns 3.04% of the company’s shares, worth $2.09M. The average tenure of the management team and the board of directors is 4.3 years and 8.9 years respectively.
Key information
Rick Miller
Chief executive officer
US$524.2k
Total compensation
| CEO salary percentage | 57.2% |
| CEO tenure | 10.2yrs |
| CEO ownership | 3.0% |
| Management average tenure | 4.3yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$524k | US$300k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$905k | US$300k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$1m | US$300k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$48m |
| Dec 31 2019 | US$1m | US$300k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$1m | US$300k | -US$47m |
| Sep 30 2018 | n/a | n/a | -US$48m |
| Jun 30 2018 | n/a | n/a | -US$51m |
| Mar 31 2018 | n/a | n/a | -US$54m |
| Dec 31 2017 | US$1m | US$302k | -US$56m |
Compensation vs Market: Rick's total compensation ($USD524.24K) is about average for companies of similar size in the US market ($USD677.87K).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
CEO
Rick Miller (72 yo)
10.2yrs
Tenure
US$524,239
Compensation
Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.2yrs | US$524.24k | 3.04% $ 2.1m | |
| Co-Founder & Independent Director | no data | US$67.80k | 0% $ 0 | |
| Chief Financial Officer | 9.4yrs | US$497.85k | 0.58% $ 395.4k | |
| Senior Vice President of Pharmaceutical Development | 4.3yrs | US$455.54k | 0.27% $ 187.3k | |
| Senior Vice President of Research | 1.8yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
4.3yrs
Average Tenure
66yo
Average Age
Experienced Management: CRVS's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.3yrs | US$524.24k | 3.04% $ 2.1m | |
| Co-Founder & Independent Director | 9.4yrs | US$67.80k | 0% $ 0 | |
| Independent Director | 9.4yrs | US$73.80k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$69.80k | 0.020% $ 14.0k | |
| Independent Director | 7.3yrs | US$65.80k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$81.80k | 0% $ 0 |
8.9yrs
Average Tenure
65.5yo
Average Age
Experienced Board: CRVS's board of directors are considered experienced (8.9 years average tenure).